ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
90.54
Bid
-
Ask
-
Volume
-
0.00 Day's Range 0.00
72.39 52 Week Range 93.97
Market Cap
Previous Close
90.54
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
377,759
Shares Outstanding
60,177,003
Dividend Yield
1.33%
PE Ratio
33.68
Earnings Per Share (EPS)
2.69
Revenue
4.9B
Net Profit
161.79M

About MAXIMUS Inc

Maximus Inc is an operator of government health and human services programs in the United States, United Kingdom, Canada, Australia, and Saudi Arabia. The company offers business solutions to improve the cost-effectiveness, efficiency, and quality of government-sponsored benefit programs, such as Me... Maximus Inc is an operator of government health and human services programs in the United States, United Kingdom, Canada, Australia, and Saudi Arabia. The company offers business solutions to improve the cost-effectiveness, efficiency, and quality of government-sponsored benefit programs, such as Medicaid, Medicare, Health Insurance BC, and child support programmes. Most of its revenue is derived from long-term contractual arrangements with governments around the world. The largest segment by revenue, health services, provides customer center operations and support services, health insurance enrollment services, and health plan oversight services. Show more

Sector
Business Services, Nec
Industry
Management Consulting Svcs
Website
Headquarters
Richmond, Virginia, USA
Founded
2010
MAXIMUS Inc is listed in the Business Services sector of the New York Stock Exchange with ticker MMS. The last closing price for MAXIMUS was $90.54. Over the last year, MAXIMUS shares have traded in a share price range of $ 72.39 to $ 93.97.

MAXIMUS currently has 60,177,003 shares outstanding. The market capitalization of MAXIMUS is $5.45 billion. MAXIMUS has a price to earnings ratio (PE ratio) of 33.68.

MMS Latest News

Maximus Awarded $40 Million Task Order Under IRS Transformational Enterprise Development, Operations Service (EDOS) Contract

Maximus expands role under second EDOS task order delivering modernized services for the IRS Enterprise Data Platform (EDP) Maximus (NYSE: MMS), a leading employer and provider of government...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
13.283.7588815035587.2690.5987.12539660788.83471801CS
4-0.35-0.38508086698290.8993.784.5832469489.24622447CS
124.515.2423573172186.0393.9784.0837775988.84002661CS
266.88.120372581883.7493.9779.133404386.58975677CS
5212.2915.706070287578.2593.9772.3933483383.57036258CS
1568.179.918659706282.3793.9754.4635025476.8385087CS
26010.4713.076058448980.0796.0546.4236470875.92412871CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ATUSAltice USA Inc
$ 2.46
(7.89%)
57
NKENike Inc
$ 86.50
(6.82%)
211.25k
BIGZBlackRock Innovation and Growth Term Trust
$ 7.99
(5.13%)
1
AEVAAeva Technologies Inc
$ 3.31
(5.08%)
9
TIXTTELUS International Cda Inc
$ 3.81
(4.38%)
30
FDXFedEx Corp
$ 260.50
(-13.28%)
40.39k
FAMFirst Trust abrdn Global Opportunity Income Fund
$ 6.01
(-8.66%)
2
HAFNHafnia Ltd
$ 7.32
(-5.18%)
27.37k
ADNTAdient plc
$ 21.43
(-5.14%)
1.83k
SOSSOS Limited
$ 0.60
(-5.07%)
544
NIONIO Inc
$ 5.36
(-0.74%)
319.83k
PLTRPalantir Technologies Inc
$ 35.88
(-2.58%)
255.84k
NKENike Inc
$ 86.50
(6.82%)
211.25k
XPEVXPeng Inc
$ 9.73
(3.62%)
141.5k
BABAAlibaba Group Holding Limited
$ 89.37
(0.99%)
81.84k

MMS Discussion

View Posts
MiamiGent MiamiGent 2 years ago
MMS Maximus Sees FY23 Revenue $4.75B-$4.90B Vs $4.65B Est., Adj. EPS $3.70-$4.00 Vs $3.36 Est.,
By Benzinga — 4:49 PM ET 11/21/22

https://stockcharts.com/h-sc/ui?s=MMS

FY23 Outlook
Maximus is establishing fiscal year 2023 guidance. The company expects revenue to range between $4.75 billion and $4.90 billion. Adjusted operating income is expected to range between $390 million and $415 million which excludes an estimated $94 million of expense for amortization of intangible assets. Adjusted diluted earnings per share is expected to range between $3.70 and $4.00 per share.
0
👍️0
EddardStock EddardStock 7 years ago
http://m.marketwired.com/press-release/macarthur-minerals-opens-asx-ipo-offer-macarthur-australia-limited-raise-up-a10-million-tsx-venture-mms-2203943.htm
👍️0
EddardStock EddardStock 7 years ago
https://www.juniorminingnetwork.com/junior-miner-news/press-releases/1270-tsx-venture/mms/29276-macarthur-minerals-singaporean-steel-and-shipping-group-signs-funding-mandate-for-macarthur-minerals-australian-iron-ore-project.html
👍️0
EddardStock EddardStock 7 years ago
Let's get some chatter going here big things coming in the very near future!!
👍️0
ValueInvestor15 ValueInvestor15 8 years ago
Cashflow models show MMS has 28% upside before earnings: Valuation

👍️0
ClayTrader ClayTrader 8 years ago
* * $MMS Video Chart 07-15-16 * *

Link to Video - click here to watch the technical chart video
👍️0
magness magness 9 years ago

20% drop

is too extreme. MMS is a great company.
👍️0
mick mick 11 years ago

cramer and company.

http://www.mainstreet.com/

http://www.mainstreet.com/article/money/investing/marijuana-legalization-changes-tune-private-investors

Marijuana Legalization Changes the Tune of Private Investors
By Juliette Fairley



[-chart]i.thestreet.com/files/tsc/v2008/photos/all-pics/mainstreet/moneyweed-front-offlead.jpg[/chart]


pg.#1
NEW YORK (MainStreet) — It used to be that private equity firms, mutual fund managers and venture capitalists would hang up on telephone calls from Medical Marijuana Sciences (MMS), but since cannabis went legit in Colorado on January 1, the company's phones have been ringing off the hook.

"Wall Street players are paying attention to us because marijuana is the new gold rush," said Tim Matula, president of MMS.

Most of the people calling are from private equity firms and mutual funds in addition to venture capitalists and accredited investors seeking to invest in the company's proprietary technology.

"We've had a 90% increase in calls since the New Year and five or six offers for funding in the $10 million dollar range in the past three months," Matula told MainStreet.

MMS is one of many marijuana related companies that are receiving interest from private investors.

"A new crop of private equity and angel investment firms are specializing in ancillary marijuana companies," said David Downs, editor of the San Francisco Chronicle's pot blog Smell The Truth. "The Arc View Group is pooling tens of millions of dollars to invest in companies that assist the marijuana business in technology, IT infrastructure, packaging, inventory, supply, etc. There's also Emerald Ocean Capital and Privateer, which are deep pocketed."

Emerald Ocean Capital declined to comment and calls to Arc View went unreturned.

"It's a business," said Rex Maceo, senior vice president and chief investment officer with Wilmington Trust, the investment advisory arm of M&T Bank in Atlanta. "Private equity firms want to know the marijuana company's cash flow, valuation and exit strategy as well as who the competition is. It's hard to figure out who the winner is going to be. Investors want to know if their investment is going to win regardless of how the industry shakes out."

pg.#2
http://www.mainstreet.com/article/money/investing/marijuana-legalization-changes-tune-private-investors?page=2



[-chart]i.thestreet.com/files/tsc/v2008/photos/all-pics/mainstreet/moneyweed-front-offlead.jpg[/chart]

As a wholly owned subsidiary of Nuvilex, MMS is researching the use of marijuana to treat cancer and other diseases.

But because MMS is not using cannabis in its traditional form, the company is not subject to the same SEC, IRS or federal scrutiny as a marijuana grower or dispensary.

"We do not employ the THC compounds contained in the plant based drug so we do not have the same legal obstacles that other marijuana companies have," Waggoner told MainStreet.

Headquartered in Silver Spring, Md., MMS raised $4 million a year ago to pay for the company's late stage clinical trials through a series of accredited investors buying stock in Nuvilex.

"In fielding new offers, we're looking for the best deal we can get," Waggoner said. "We want to partner with a firm that understands what we are doing but we're not willing to give the company away."

--Written by Juliette Fairley for MainStreet

mms

Maximus, Inc. (MMS

http://investorshub.advfn.com/Maximus-Inc-MMS-27532/



[-chart]ih.advfn.com/p.php?pid=staticchart&s=MMS&p=0&t=17&showctype=1&width=336&height=190&vol=1&afterhours=130[/chart]

👍️0
ECole ECole 11 years ago
Q4 earnings transcript


http://www.earningsimpact.com/Transcript/84520/MMS/Q4-2013-Earnings-Call
👍️0

Your Recent History

Delayed Upgrade Clock